Cargando…
Reply to Dorgham et al., “Considering Personalized Interferon Beta Therapy for COVID-19”
Autores principales: | Davoudi-Monfared, Effat, Khalili, Hossein |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Society for Microbiology
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8097451/ https://www.ncbi.nlm.nih.gov/pubmed/33558288 http://dx.doi.org/10.1128/AAC.00083-21 |
Ejemplares similares
-
Considering Personalized Interferon Beta Therapy for COVID-19
por: Dorgham, Karim, et al.
Publicado: (2021) -
The threat of carbapenem-resistant gram-negative bacteria in a Middle East region
por: Davoudi-Monfared, Effat, et al.
Publicado: (2018) -
In Reply to Özkıdık et al.
por: Bozkurt, Hasan, et al.
Publicado: (2018) -
Reply to Sarridou et al.
por: Koster, Andreas, et al.
Publicado: (2021) -
Reply to Romano et al.
por: Santhirakumaran, Gowthanan, et al.
Publicado: (2022)